NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
Part of paid clinical trials in Mountain View, California.
- Sponsor
- Northern California Retina Vitreous Associates
- Study ID
- NCT01870427
- Phase
- PHASE4
- Status
- Completed
Conditions
- Macular Edema With Central Retinal Vein Occlusions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 100 Years
- Healthy Volunteers
- Not accepted
Interventions
- Aflibercept (2.0 mg) — DRUGIntravitreal Aflibercept (2.0 mg)
Study Details
The purpose of the study is to determine the effect of Intravitreal Aflibercept Injection (IAI) on previously treated Central Retinal Vein Occlusions (CRVOs) with other Anti-VEGF agents.
Key Dates
- Start date
- Jun 30, 2013
- Status verified
- Dec 2016
- Primary completion
- Aug 31, 2015
- Completion
- Aug 31, 2016
Study Design
- Enrollment
- 20 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Aflibercept (2.0 mg)Intravitreal Aflibercept (2.0 mg)
Primary Outcome Measure
Duration of Intravitreal Aflibercept on Treatment Interval [ Time Frame: 52 Weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Northern California Retina Vitreous Associates | Mountain View | California | 94040 | - |